OBJECTIVE: To establish the long term recurrence rate in patients operated on for nodular goitre and to find out if oral treatment with thyroxine reduces this risk. DESIGN: Retrospective study. SETTING: District hospital, Sweden. SUBJECTS: 43 patients who underwent subtotal thyroidectomy for nodular goitre (36 non-toxic, 7 toxic) from 1960-65, and who were re-examined in 1993; 11 patients were given oral thyroxine during the postoperative period and the remaining 32 had no medical treatment. MAIN OUTCOME MEASURES: Recurrence of goitre. RESULTS: 5/11 goitres recurred in the thyroxine group (45%) and 13/32 (41%) in the untreated group. CONCLUSION: The recurrence rate of nodular goitre is high 30 years after subtotal thyroidectomy. Long term oral thyroxine does not seem to change the picture.
OBJECTIVE: To establish the long term recurrence rate in patients operated on for nodular goitre and to find out if oral treatment with thyroxine reduces this risk. DESIGN: Retrospective study. SETTING: District hospital, Sweden. SUBJECTS: 43 patients who underwent subtotal thyroidectomy for nodular goitre (36 non-toxic, 7 toxic) from 1960-65, and who were re-examined in 1993; 11 patients were given oral thyroxine during the postoperative period and the remaining 32 had no medical treatment. MAIN OUTCOME MEASURES: Recurrence of goitre. RESULTS: 5/11 goitres recurred in the thyroxine group (45%) and 13/32 (41%) in the untreated group. CONCLUSION: The recurrence rate of nodular goitre is high 30 years after subtotal thyroidectomy. Long term oral thyroxine does not seem to change the picture.
Authors: Marcin Barczyński; Aleksander Konturek; Alicja Hubalewska-Dydejczyk; Filip Gołkowski; Stanisław Cichoń; Wojciech Nowak Journal: World J Surg Date: 2010-06 Impact factor: 3.352
Authors: M Alba; D Fintini; R M Lovicu; R M Paragliola; G Papi; C A Rota; A Pontecorvi; S M Corsello Journal: J Endocrinol Invest Date: 2009-04 Impact factor: 4.256